Home / Market News / $OMAB
benzinga Corporate Catalyst Impact 65/100 ● neutral

OmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Receive An Upfront Payment and Is Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments

Aug 17, 2026, 10:07 AM UTC · Primary ticker $OMAB

OmniAb has entered into a global collaboration and license agreement with Eli Lilly for a new ion channel program. OmniAb will receive an upfront payment and is eligible for up to $370 million in R&D and commercial milestone payments, indicating potential future revenue streams.

OmniAb announced a global collaboration and license agreement with Eli Lilly for an undisclosed ion channel program. This deal includes an upfront payment to OmniAb and potential milestone payments totaling up to $370 million, which is a significant financial boost for OmniAb. For OmniAb, this represents a positive development, providing non-dilutive funding and validating its technology platform. For Eli Lilly, it signifies an expansion of its R&D pipeline, though the specific therapeutic target and modality remain undisclosed, limiting immediate detailed analysis of its impact. Short-term, OmniAb shareholders may see a positive reaction due to the upfront payment and future revenue potential. Long-term, the success of the collaboration and the achievement of milestones will determine the full impact for both companies. Traders should monitor OmniAb for potential upside driven by this new partnership and future updates on the program's progress.

$OMAB positive Upfront payment and potential milestones
$LLY neutral New program, undisclosed details
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.